API | surufatinib

surufatinib Report issue

Small molecule Experimental

Active Ingredient History

NOW

Now

Chemistry

SMILES: Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
InChIKey: TTZSNFLLYPYKIL-UHFFFAOYSA-N
Mol. Mass: 480.59
ALogP: 3.78 Partition coefficient
ChEMBL Molecule:
surufatinib

More Chemistry

Pharmacology

Mechanisms of Action:
- Fibroblast growth factor receptor 1 (Homo sapiens) ^UniProt
- Macrophage colony-stimulating factor 1 (Homo sapiens) ^UniProt
- Vascular endothelial growth factor receptor 1 (Homo sapiens) ^UniProt
- Vascular endothelial growth factor receptor 2 (Homo sapiens) ^UniProt
- Vascular endothelial growth factor receptor 3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (32)

Research & Development (32)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (42)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (42)

Adenocarcinoma (Phase 2)

Angiogenesis Inhibitors (Phase 2)

Angiogenesis Modulating Agents (Phase 2)

Antineoplastic Agents, Immunological (Phase 2)

Bile Duct Neoplasms (Phase 2)

Biliary Tract Neoplasms (Phase 2/Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cholangiocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Drugs, Investigational (Phase 2)

Exocrine Pancreatic Insufficiency (Phase 1)

Fallopian Tube Neoplasms (Phase 1/Phase 2)

Gallbladder Neoplasms (Phase 2)

Hamartoma (Phase 2)

Healthy Volunteers (Phase 1)

Immunotherapy (Phase 2)

Intestinal Neoplasms (Phase 2)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1/Phase 2)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 3)

Osteosarcoma (Phase 1/Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Rhabdomyosarcoma (Phase 1/Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 1/Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Thyroid Carcinoma, Anaplastic (Phase 1/Phase 2)

Thyroid Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 66
# of Trial Organizations: 32

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue